What is LifeSprout?
Founded in 2015 by a distinguished cohort of scientists and surgeons from Johns Hopkins University, LifeSprout specializes in the development of advanced soft tissue restoration products. The company leverages sophisticated materials science to engineer solutions that effectively mimic the body's natural tissue architecture. This innovation is critical for addressing soft tissue deficits resulting from aging, oncological procedures, and metabolic conditions. By prioritizing patient outcomes through products that offer enhanced form and function with reduced recovery times, LifeSprout is effectively disrupting the traditional aesthetic and reconstructive markets. Their commitment to scientific integrity and clinical excellence positions them as a leader in the next generation of bio-restorative therapies.
How much funding has LifeSprout raised?
LifeSprout has raised a total of $35.1M across 3 funding rounds:
Angel/Seed
$6.5M
Debt
$150K
Series A
$28.5M
Angel/Seed (2019): $6.5M with participation from Ginkgo Gofar, Medytox, Inc., Angel MD, Kairos Venture Partners, Triskelion Investments, and Maryland Technology Development Corporation
Debt (2020): $150K led by PPP
Series A (2020): $28.5M supported by emeraldmanagers.com, Abell Foundation Inc, Nexus Management Inc, and Redmile Group , LLC
Key Investors in LifeSprout
Maryland Technology Development Corporation
TEDCO is a Maryland-based organization that provides funding, resources, and connections to early-stage technology and life sciences companies to foster innovation and entrepreneurship.
Redmile Group, LLC
A healthcare-focused investment firm that provides capital to life sciences companies at various stages of development.
Kairos Venture Partners
A venture capital firm that partners with world-class scientists to commercialize breakthrough technologies and build high-growth companies.
What's next for LifeSprout?
With the recent influx of capital, LifeSprout is well-positioned to accelerate its clinical development programs and expand its manufacturing capabilities. The strategic focus will likely shift toward navigating regulatory pathways and scaling commercial distribution to meet the growing demand for minimally invasive restorative solutions. As the company transitions into a more mature enterprise phase, the emphasis will remain on validating its technology across broader patient demographics and establishing a robust footprint in the global medical device landscape. Continued investment in research and development will be paramount as LifeSprout seeks to broaden its product suite and solidify its competitive advantage in the high-growth regenerative medicine sector.
See full LifeSprout company page
